RxDoctor Payments DataLook up a doctor →

Woodrow Coker, MD

Hospitalist · Charleston, SCNPI 1508028366

Payments from drug & device makers

$14,255in general payments, 2019–2025

Across 696 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$928
  • Johnson & Johnson$756
  • E.r. Squibb & Sons, L.L.C.$675
  • Merck$666
  • Takeda Pharmaceuticals U.S.A., Inc.$645
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$13,91298%
  • Education$440%
  • Other$2992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis57$1,491
AstraZeneca(2 entities)51$928
Johnson & Johnson(2 entities)35$756
E.r. Squibb & Sons, L.L.C.47$675
Merck28$666
Takeda Pharmaceuticals U.S.A., Inc.33$645
Pfizer38$619
Bristol Myers Squibb27$503
Lilly USA, LLC22$465
Daiichi Sankyo Inc.19$456
Genentech USA, Inc.27$426
AbbVie19$368
Astellas Pharma US Inc17$316
EMD Serono, Inc.13$283
Incyte Corporation14$283
Eisai Inc.13$274
Heron Therapeutics, Inc.1$254
GSK10$249
AVEO Pharmaceuticals, Inc.10$234
Amgen12$222
Sanofi8$214
Gilead11$212
Seagen Inc.12$196
Puma Biotechnology, Inc.11$187
Eagle Pharmaceuticals, Inc.3$174
Taiho Oncology, Inc.8$154
Octapharma USA, Inc.1$152
Exelixis Inc.10$144
Bayer9$143
Array Biopharma Inc11$139
Karyopharm Therapeutics Inc.8$137
Deciphera Pharmaceuticals Inc.5$137
Ipsen Biopharmaceuticals, Inc7$136
Jazz Pharmaceuticals Inc.8$135
Janssen Scientific Affairs, LLC1$119
Sumitomo Pharma America, Inc.6$118
Foundation Medicine, Inc.1$115
Regeneron Healthcare Solutions, Inc.5$112
Rigel Pharmaceuticals, Inc.4$100
Beone Medicines USA, Inc.5$94
Boehringer Ingelheim4$93
Beigene USA, Inc.5$80
Pharmacyclics LLC, An Abbvie Company5$69
Spectrum Pharmaceuticals Inc.3$64
ADC Therapeutics America, Inc.3$59
Mirati Therapeutics, Inc.3$56
Springworks Therapeutics, Inc.3$50
Sobi, Inc3$48
Servier Pharmaceuticals LLC2$48
Macrogenics, Inc.2$47
Stemline Therapeutics Inc.2$47
Genmab U.S., Inc.2$46
Kyowa Kirin, Inc.3$43
Blueprint Medicines Corporation3$39
Pharmacosmos Therapeutics Inc.2$37
Clovis Oncology, Inc.2$32
Morphosys, US Inc.2$31
Tersera Therapeutics LLC2$29
Helsinn Therapeutics (U.S.), Inc.2$27
Genentech, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,255 in reported general payments places this provider in the 95th percentile of 398 hospitalist providers in South Carolina.

See all hospitalist providers in South Carolina

Medicare billing

Part B allowed, 2024
$6,998,372
Medicare patients
1,213
Services billed
348,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide19$326,926
ImbruvicaIbrutinib14$223,936
BrukinsaZanubrutinib13$188,497
NyvepriaPegfilgrastim-Apgf14$53,585
EliquisApixaban48$35,315
XareltoRivaroxaban18$17,372
Ondansetron OdtOndansetron62$2,503
Fentanyl12$1,173
Prochlorperazine Maleate76$1,069
Dexamethasone73$1,049
Potassium Chloride63$931
Anastrozole45$919
Acyclovir50$878
Oxycodone Hcl46$725
Morphine Sulfate ErMorphine Sulfate21$721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$503$326,92619 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$69$223,93614 claims
Beigene USA, Inc.Brukinsa$80$188,49713 claims
PfizerNyvepria, Eliquis$619$88,90062 claims
Johnson & JohnsonXarelto$756$17,37218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 398 hospitalist providers in South Carolina.

Other hospitalist in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →